ClinicalTrials.gg

Program

SHR-2004

A development code. Also written as “SHR-2004 injection” and “SAD, SHR-2004”.

In Jiangsu HengRui Medicine's pipeline, FXI. Its studies are mostly in Venous Thrombosis · Atrial Fibrillation · Ovarian Neoplasms · Venous Thromboembolism, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Feb 9, 20255 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine50 open or runningphase 3since Feb 9, 2025May 6, 2022none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-2004, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 6, 2022First study: phase 1 study in Venous ThrombosisFirst studyNCT05369767 · 64 enrolled · China
  2. Feb 22, 2023Phase 2 study in Prevention of Venous Thromboembolism After Knee ArthroplastyNCT05752461 · 353 enrolled · China
  3. Jan 12, 2024Phase 2 study in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer SurgeryNCT06220123 · 225 enrolled · China
  4. Feb 20, 2024Phase 1 study in Atrial FibrillationNCT06280768 · 10 enrolled · China
  5. Feb 9, 2025Phase 3 study in Venous ThrombosisNCT06825416 · 1,165 enrolled · China

TargetBeta

“FXI”the company's pipeline, read by Claude · source

Other programs on F11

ProgramCompanyFurthest phaseStudies
milvexianBristol-Myers Squibbphase 325
abelacimabanthos-therapeutics-incphase 38

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06825416Venous Thrombosis · China3CompletedFeb 15, 20261,165
NCT06280768Atrial Fibrillation · China1CompletedJan 10, 202510
NCT06220123Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery · China2CompletedDec 31, 2024225
NCT05752461Prevention of Venous Thromboembolism After Knee Arthroplasty · China2CompletedApr 12, 2024353
NCT05369767Venous Thrombosis · China1UNKNOWNJan 30, 202364

How it is read

Names in the registry

  • “SHR-2004 injection”, 6 entries
  • “SHR-2004”, 1 entry
  • “SAD, SHR-2004”, 1 entry

Codes read as this program: SHR2004.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.